文献速递主动脉疾病

八旬以上患者开窗腔内动脉瘤修复术的多中心回顾性结局分析

Outcome of Fenestrated Endovascular Aneurysm Repair in Octogenarians: A Retrospective Multicentre Analysis.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2019-11-11

本研究回顾性分析两个中心2001至2016年接受开窗腔内动脉瘤修复术(FEVAR)的复杂腹主动脉瘤患者,比较80岁及以上组(42例)与80岁以下组(230例)的围手术期结局及随访结果。结果显示两组总生存率、再干预自由生存率及靶血管通畅率均无显著差异,提示年龄本身不应作为拒绝FEVAR的理由。

要点

  • 治疗选择应基于患者合并症和偏好,而非单纯年龄。

核心结论

  • 年龄本身不是拒绝为老年患者行FEVAR的理由,治疗选择应基于合并症和患者偏好。

研究设计与样本

  • 多中心回顾性分析,纳入2001至2016年两个三级转诊中心因复杂腹主动脉瘤接受FEVAR的患者。
  • Group 1为80岁及以上患者42例(中位年龄82岁,IQR 81-83岁),Group 2为80岁以下患者230例(中位年龄72岁,IQR 67-77岁)。

主要发现

  • 术前合并症除年龄和肾功能外无差异,肾功能分别为61.4 mL/min/1.73 m2和74.5 mL/min/1.73 m2(p < .01)。
  • 中位随访分别为26个月和32个月,1、3、5年估计累积总生存率Group 1为95%、58%、42%,Group 2为88%、75%、61%(p = .08)。
  • 1、3、5年估计累积再干预自由生存率Group 1为84%、84%、84%,Group 2为88%、84%、82%(p = .95)。
  • 1、3、5年估计累积靶血管通畅率Group 1为100%、100%、90%,Group 2为96%、93%、92%(p = .56)。

临床怎么用

  • 对于高龄复杂腹主动脉瘤患者,FEVAR的围手术期及中期结局与年轻患者相当,可作为治疗选项。
  • 决策时应综合评估合并症(尤其是肾功能)和患者偏好,而非仅凭年龄排除FEVAR。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: An ageing population leads to more age related diseases, such as complex abdominal aortic aneurysms (AAA). Patients with complex AAAs and multiple comorbidities benefit from fenestrated endovascular aneurysm repair (FEVAR), but for the elderly this benefit is not completely clear. METHODS: Between 2001 and 2016 all patients treated for complex AAA by FEVAR at two tertiary referral centres were screened for inclusion. Group 1 consisted of patients aged 80 years and older and group 2 of patients younger than 80 years of age. The groups were compared for peri-operative outcome, as well as patient and re-intervention free survival, and target vessel patency during follow up. RESULTS: Group 1 consisted of 42 patients (median age 82 years; interquartile range [IQR] 81-83 years) and group 2 of 230 patients (median age 72 years; IQR 67-77 years). No differences were seen in pre-operative comorbidities, except for age and renal function. Renal function was 61.4 mL/min/1.73 m2vs.74.5 mL/min/1.73 m2 (p < .01). No differences were seen between procedures, except for a slightly longer operation time in group two. Median follow up was 26 and 32 months, respectively. No difference was seen between the groups for estimated cumulative overall survival (p = .08) at one, three, and five years, being 95%, 58%, and 42% for group 1, and 88%, 75%, and 61% for group 2, respectively. There was no difference seen between groups for the estimated cumulative re-intervention free survival (p = .95) at one, three, and five years, being 84%, 84%, and 84% in group 1, respectively, and 88%, 84%, and 82% in group 2, respectively. Ultimately, no difference was seen between groups for the estimated cumulative target vessel patency (p = .56) at one, three, and five years, being 100%, 100%, and 90% for group 1, and 96%, 93% and 92% for group 2, respectively. CONCLUSION: Age itself is not a reason to withhold FEVAR in the elderly, and choice of treatment should be based on the patient's comorbidities and preferences.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Henstra L, Yazar O, de Niet A, et al. Outcome of Fenestrated Endovascular Aneurysm Repair in Octogenarians: A Retrospective Multicentre Analysis. Eur J Vasc Endovasc Surg. 2019. PMID: 31727436. doi:10.1016/j.ejvs.2019.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。